find a clinical trial
If you have any questions or are interested in participating in one of our Clinical Trials, please take note of the associated protocol number and contact our team at 201-518-3587, or email us.
298
Clinical Trials
Lymphoma
Phase II
Accepting Patients
nct/study# NCT03467867 / PRO2018-0577
A Phase II Study Of Venetoclax And Rituximab/Hyaluronidase Human In Relapsed/Refractory CLL
Learn More
Lymphoma
Phase I/II
Accepting Patients
nct/study# NCT02956382 / PRO2016-0014-C103287
Ibrutinib And Venetoclax In Relapsed And Refractory Follicular Lymphoma
Learn More
Lymphoma
Phase I/II
Accepting Patients
nct/study# NCT04623541 / GCT3013-03
A Phase 1b/2, Open-Label, Safety And Efficacy Study Of Epcoritamab (GEN3013; Duobody®-CD3 X CD20) In Relapsed/Refractory Chronic Lymphocytic Leukemia
Learn More
Lymphoma
Phase I
Accepting Patients
nct/study# NCT04663347 / GCT3013-02
A Phase 1b/2, Open-Label Trial To Assess The Safety And Preliminary Efficacy Of Epcoritamab (GEN3013; Duobody®-CD3xCD20) In Combination With Other Agents In Subjects With B-Cell Non-Hodgkin Lymphoma
Learn More
Lymphoma
Phase I
Accepting Patients
nct/study# NCT03328078 / CA-4948-101
An Open-Label, Dose Escalation And Dose Expansion Trial Evaluating The Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of Orally Administered CA-4948 In Patients With Relapsed Or Refractory Hematologic Malignancies
Learn More
Lymphoma
Phase I/II
Accepting Patients
nct/study# NCT03420183 / ONCTERNAL-CIRM-0001
A Phase 1b-2 Study Of The ROR1-Targeting Monoclonal Antibody, Cirmtuzumab (UC-961), And The Bruton Tyrosine Kinase Inhibitor, Ibrutinib, In Patients With B-Cell Lymphoid Malignancies
Learn Morewe are here for you
For more information or to schedule an appointment,
call 844-346-7222. You can also schedule an appointment by calling the RCCA location nearest you.
Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.